Oncopeptides AB (ONCO):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Oncopeptides AB (ONCO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8255
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:31
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Oncopeptides AB (Oncopeptides) is a clinical development pharmaceutical company that offers development of oncology therapies to treat multiple myeloma. The company’s lead product candidate Ygalo (melflufen) is a peptidase potentiated cytotoxic drug and a potent anti-angiogenetic compound, among others. Its Ygalo is intended for the treatment of patients with late-stage relapsed and refractory multiple myeloma. Oncopeptides initiated an additional Phase II clinical trial of Ygalo in combination with dexamethasone. The company conducts Ygalo’s clinical study in collaboration with other institutions across the US and Europe including Dana-Farber Cancer Institute. Oncopeptides is headquartered in Stockholm, Sweden.

Oncopeptides AB (ONCO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Oncopeptides AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Oncopeptides AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Oncopeptides AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Oncopeptides AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Oncopeptides AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Oncopeptides AB, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Oncopeptides Raises Funds Through Series A Financing 10
Equity Offering 12
Oncopeptides Raises USD19.5 Million in Private Placement of Shares 12
Oncopeptides Raises USD38.4 Million in Public Offering of Shares 13
Oncopeptides Raises USD84.3 Million in IPO 14
Oncopeptides AB – Key Competitors 15
Oncopeptides AB – Key Employees 16
Oncopeptides AB – Locations And Subsidiaries 17
Head Office 17
Recent Developments 18
Financial Announcements 18
Jul 13, 2018: Oncopeptides: Interim report April-June 2018 18
May 17, 2018: Oncopeptides Interim report January – March 2018 19
Feb 22, 2018: Oncopeptides Year-end report 2017 20
Nov 15, 2017: Oncopeptides Interim Report July-September 2017 21
Aug 25, 2017: Oncopeptides: Interim Report April – June 2017 22
Corporate Communications 23
Aug 09, 2018: Anders Martin-Lof has been appointed as the new CFO of Oncopeptides 23
Mar 26, 2018: Oncopeptides Names Dr Christian Jacques As EVP Clinical Strategy And Chief Scientific Officer 24
Clinical Trials 25
Dec 10, 2017: Oncopeptides presented survival data from the phase II-study O-12-M1 of Ygalo (melflufen) at the 59th Annual Meeting of ASH 25
Dec 09, 2017: Oncopeptides presented interim data from the ongoing phase II study HORIZON with Ygalo (melflufen) at the 59th Annual Meeting of ASH 26
Nov 07, 2017: Oncopeptides to attend the Jefferies Healthcare Conference in London on November 16th 27
Nov 01, 2017: Oncopeptides to present data from two clinical studies of Ygalo (melflufen) at American Society of Hematology, December 9-12. 28
Jun 14, 2017: First patient dosed in the pivotal phase III study OCEAN with Ygalo 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31

List of Tables
Oncopeptides AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Oncopeptides AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Oncopeptides AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Oncopeptides AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Oncopeptides AB, Deals By Therapy Area, 2012 to YTD 2018 8
Oncopeptides AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Oncopeptides Raises Funds Through Series A Financing 10
Oncopeptides Raises USD19.5 Million in Private Placement of Shares 12
Oncopeptides Raises USD38.4 Million in Public Offering of Shares 13
Oncopeptides Raises USD84.3 Million in IPO 14
Oncopeptides AB, Key Competitors 15
Oncopeptides AB, Key Employees 16

List of Figures
Oncopeptides AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Oncopeptides AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Oncopeptides AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Oncopeptides AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Oncopeptides AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Oncopeptides AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Oncopeptides AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Oncopeptides AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Oncopeptides AB (ONCO):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Anglo American Plc:企業の戦略・SWOT・財務情報
    Anglo American Plc - Strategy, SWOT and Corporate Finance Report Summary Anglo American Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Mayne Pharma Group Ltd (MYX):製薬・医療:M&Aディール及び事業提携情報
    Summary Mayne Pharma Group Ltd (Mayne Pharma), formerly HalcyGen Pharmaceuticals Ltd, a subsidiary of Mayne Pharma Group Ltd, is a specialty pharmaceutical company that manufactures and markets branded and generic medicinal products. The company’s products comprise erymax capsules, kapanol capsules, …
  • Exploration and Production KazMunaiGas (KMG):石油・ガス:M&Aディール及び事業提携情報
    Summary Exploration and Production KazMunaiGas (KMG EP), a subsidiary of National Company KazMunaiGas, is an upstream oil and gas company. The company carries out the exploration, development, production, processing and export of hydrocarbons and acquisition of oil and gas assets in Kazakhstan. Its …
  • Hospira Inc:医療機器:M&Aディール及び事業提携情報
    Summary Hospira Inc (Hospira), a subsidiary of Pfizer Inc, is a medical device company that offers injectable drugs and infusion technologies. The company offers products such as generic acute-care and oncology injectables, biosimilars, infusion systems, IV sets, IV safety devices, biosimilars, diff …
  • Pareteum Corp (TEUM):企業の財務・戦略的SWOT分析
    Pareteum Corp (TEUM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Biogen, Inc.:戦略・SWOT・企業財務分析
    Biogen, Inc. - Strategy, SWOT and Corporate Finance Report Summary Biogen, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Konica Minolta, Inc.:企業の戦略・SWOT・財務情報
    Konica Minolta, Inc. - Strategy, SWOT and Corporate Finance Report Summary Konica Minolta, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Hirose Electric Co Ltd (6806):企業の財務・戦略的SWOT分析
    Hirose Electric Co Ltd (6806) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Powerco Ltd:企業の戦略的SWOT分析
    Powerco Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Leukemia & Lymphoma Society Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary The Leukemia & Lymphoma Society Inc (LLS) is a voluntary health organization that focuses on funding research for identifying cure for blood cancer. The organization also assures access to treatments for blood cancer patients. Its offers patient support, health education, policy advocacy, an …
  • Daikin Industries Ltd (6367):企業の財務・戦略的SWOT分析
    Daikin Industries Ltd (6367) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Majesco
    Majesco - Strategy, SWOT and Corporate Finance Report Summary Majesco - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Carna Biosciences Inc (4572):企業の財務・戦略的SWOT分析
    Summary Carna Biosciences Inc (Carna) is a biotechnology company that discovers and develops drugs for the treatment of cancer and inflammatory diseases. The company offers products such as kinase proteins, biotinylated kinases, substrates, assay kits, protein substrates, inactive kinases, inactive- …
  • West African Development Bank:電力:M&Aディール及び事業提携情報
    Summary West African Development Bank (BOAD) is a public financial institution focused on the balanced development of its member countries of the West African Monetary Union (WAMU). The institution offers financial advisory services; guarantees of bond loans; financial assistance in project preparat …
  • Skyworth Digital Holdings Limited:企業の戦略・SWOT・財務情報
    Skyworth Digital Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Skyworth Digital Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • NEC Corp (6701):電力:M&Aディール及び事業提携情報
    Summary NEC Corp (NEC) provides information technology and network technologies solutions. The company’s product portfolio includes servers, equipment and network systems for telecommunication carriers, supercomputers, personal computers, tablet terminals, automated teller machines, storage devices, …
  • Indago Energy Ltd (INK):石油・ガス:M&Aディール及び事業提携情報
    Summary Indago Energy Ltd (Indago), formerly Pryme Energy Ltd is a provider of specialist oil and gas production chemicals. The company offers acquisition, up-gradation, exploration and production services to onshore oil and natural gas. It holds interests in the Newkirk project located in Kay Count …
  • BELLUS Health Inc (BLU):製薬・医療:M&Aディール及び事業提携情報
    Summary BELLUS Health Inc (BELLUS Health) is a biopharmaceutical development company, which focuses on developing drugs for rare diseases. The company’s pipeline products include BLU-5937 for chronic cough, Shigamab for STEC related hemolytic syndrome (sHUS); KIACTA for the treatment of a second ind …
  • Georgia Power Co (GPW):電力:M&Aディール及び事業提携情報
    Summary Georgia Power Co (Georgia Power), a subsidiary of the Southern Power Company, generates, transmits, distributes and sells electricity. The company produces electricity using various sources of energy such as coal, nuclear, solar, gas and hydro. It supplies electricity in Georgia and to whole …
  • Foundation Medicine Inc (FMI)-製薬・医療分野:企業M&A・提携分析
    Summary Foundation Medicine Inc (Foundation Medicine), a subsidiary of F. Hoffmann-La Roche Ltd is a healthcare products provider that offers cancer care solutions. The company offers molecular information and cancer research programs. It offers clinical products which include FoundationOne for soli …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆